Melane Sampson, Author at BioTuesdays

Developments

Turnstone restructures to focus resources on advancing Phase 1 study

Turnstone Biologics (NASDAQ:TSBX) has announced restructuring initiatives that include the strategic prioritization of its pipeline, a 60% workforce reduction, and changes to its leadership team, aimed at focusing...

October 11, 2024

Developments

Health Canada clears Palisade to commence Phase 1 study of PALI-2108 in UC

Palisade Bio (NASDAQ:PALI) has announced that it has received a No Objection Letter from Health Canada for its Phase 1 clinical trial of PALI-2108 for the treatment of ulcerative colitis (UC). The orally-administered...

October 10, 2024

Developments

SI-BONE reports first in-patient procedures with TNT implant system for pelvic fractures

SI-BONE (NASDAQ:SIBN) has announced the first in-patient procedures using its iFuse TORQ TNT Implant System (TNT), designed to address anatomic and biomedical challenges of pelvic fragility fractures as opposed to...

October 10, 2024

Developments

Perimeter completes patient enrollment for pivotal trial evaluating next-gen OCT B-Series with ImgAssist AI in breast cancer surgery

Perimeter Medical Imaging AI (TSXV:PINK; OTC:PYNKF) has announced the completion of patient enrollment in a pivotal clinical study evaluating its next-generation Perimeter B-Series OCT system, which combines proprietary...

October 3, 2024

Feature

OSE Immunotherapeutics breaking through the therapeutic ceiling with first-in-class immunotherapies

OSE Immunotherapeutics (ISIN:FR0012127173; Mnemo:OSE) is developing and partnering therapies to control the immune system for immuno-oncology (IO) and immuno-inflammation with first-in-class immunotherapies from target...

October 1, 2024

Developments

Valerio acquires oncology biotech, Emglev

Valerio Therapeutics (Euronext Paris:ALVIO) has announced the acquisition of closely-held Emglev Therapeutics, a single-domain antibody-based therapeutic company and spinoff of Institut Curie, a leading cancer center in...

September 30, 2024

Developments

IRLAB enrolls last patient in trial of Pirepemat for Parkinson’s

IRLAB Therapeutics (STO:IRLAB-A; FRA:6IRA) has announced that it has enrolled the last patient in its ongoing Phase IIb study of Pirepemat for Parkingson’s disease. The company also reports that a reduction in falls has...

September 30, 2024

Developments

Beyond Air and TrillaMed deploy LungFit PH into U.S. Natal Hospital Guam NICU

Beyond Air (NASDAQ:XAIR), in partnership with TrillaMed, announced that it will provide its groundbreaking LungFit PH system to the neonatal critical care unit (NICU) at U.S. Naval Hospital Guam, enabling advanced care...

September 27, 2024

Developments

Pasithea announces preliminary Phase 1 data for study of PAS-004 in advanced cancer

Pasithea Therapeutics (NASDAQ:KTTA) has announced safety, tolerability, pharmacokinetic (PK), and preliminary efficacy data from its Phase 1 clinical trial of PAS-004 in patients with MAPK pathway driven advanced solid...

September 26, 2024

Developments

NanoViricides obtains ROFR for all antiviral drug treatments from TheraCour

NanoViricides (NYSE American:NNVC) has announced that it has signed a broad memorandum of understanding agreement granting it the right of first refusal (ROFR) for all antiviral drug developments, including trojan horse...

September 26, 2024

Author - Melane Sampson

Turnstone restructures to focus resources on advancing Phase 1 study

Health Canada clears Palisade to commence Phase 1 study of PALI-2108 in UC

SI-BONE reports first in-patient procedures with TNT implant system for pelvic fractures

Perimeter completes patient enrollment for pivotal trial evaluating next-gen OCT B-Series with ImgAssist AI in breast cancer surgery

OSE Immunotherapeutics breaking through the therapeutic ceiling with first-in-class immunotherapies

Valerio acquires oncology biotech, Emglev

IRLAB enrolls last patient in trial of Pirepemat for Parkinson’s

Beyond Air and TrillaMed deploy LungFit PH into U.S. Natal Hospital Guam NICU

Pasithea announces preliminary Phase 1 data for study of PAS-004 in advanced cancer

NanoViricides obtains ROFR for all antiviral drug treatments from TheraCour

General

More